Trial of a Tailored Message Program to Implement CHF Guidelines
|Heart Failure||Behavioral: CHF Self-management Education (Web-based Education)|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind
|Official Title:||Trial of a Tailored Message Program to Implement CHF Guidelines|
|Study Completion Date:||March 2004|
Congestive heart failure is a serious health problem in the United States and is associated with excessive morbidity and mortality. Several classes of medications have been shown to improve mortality in patients with CHF. Despite this these medications are widely under prescribed. Guidelines have been shown to improve patient outcomes and several guidelines on the management of CHF have been published. Implementation of guidelines is challenging and most strategies have focused on changing physician behavior. Patient-based interventions have been shown to be effective in implementing guidelines on CHF but they have been very labor intensive. A computer based intervention to implement CHF guidelines, if effective, would be beneficial.
Patients with CHF consume a significant proportion of healthcare resources, with exacerbations of CHF being the second most common reason for medical admission to VA medical centers. Therefore, the main objective is to understand the impact of a tailored education message program designed for direct use by patients on medical resource use. Other objectives include understanding the tools impact on patient compliance and quality of life.
Patients have been randomized to one of two groups: 1) intervention group or the 2) control group. The intervention group receives the tailored education messages program. This program assesses patients� beliefs about compliance with medications, diet, and self-monitoring. Based on identified barriers to compliance, intervention patients receive a tailored educational message to dispel these beliefs and improve compliance. The control group interacts with a generic healthcare website. Patients in both groups are monitored for hospitalization; emergent care visits, compliance with prescribed treatment and quality of life
Project work is ongoing.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00013026
|United States, Alabama|
|Birmingham VA Medical Center, Birmingham, AL|
|Birmingham, Alabama, United States, 35233|
|Principal Investigator:||Terrence M. Shaneyfelt, MPH MD||Birmingham VA Medical Center, Birmingham, AL|
|Principal Investigator:||Catarina I. Kiefe, PhD MD||Birmingham VA Medical Center, Birmingham, AL|